Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$33.5 million.

  • Inhibrx Biosciences' Net Cash Flow fell 966.65% to -$33.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.2 million, marking a year-over-year increase of 6932.94%. This contributed to the annual value of -$125.3 million for FY2024, which is 318765.71% down from last year.
  • Inhibrx Biosciences' Net Cash Flow amounted to -$33.5 million in Q3 2025, which was down 966.65% from -$30.0 million recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year Net Cash Flow high stood at $144.8 million for Q3 2023, and its period low was -$59.4 million during Q4 2023.
  • Moreover, its 3-year median value for Net Cash Flow was -$30.0 million (2025), whereas its average is -$4.4 million.
  • Per our database at Business Quant, Inhibrx Biosciences' Net Cash Flow plummeted by 12107.78% in 2024 and then skyrocketed by 35126.37% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' Net Cash Flow (Quarter) stood at -$59.4 million in 2023, then rose by 26.37% to -$43.7 million in 2024, then rose by 23.45% to -$33.5 million in 2025.
  • Its Net Cash Flow stands at -$33.5 million for Q3 2025, versus -$30.0 million for Q2 2025 and $63.9 million for Q1 2025.